Hepatitis B biotech AusperBio scores $120M Series C
AusperBio closed a $120M Series C to push its hepatitis B therapy…
InduPro scores $77M as its cancer drug starts human dosing
The Column Group led the Series B as the Seattle and Cambridge…
AusperBio closed a $120M Series C to push its hepatitis B therapy…
The Column Group led the Series B as the Seattle and Cambridge…
Sign in to your account